CDA and MTHFR polymorphisms are associated with clinical outcomes in gastroenteric cancer patients treated with capecitabine-based chemotherapy

Pharmacogenetic variants in the DPYD, TYMS, CDA and MTHFR genes are clinically significant predictors of fluoropyrimidine toxicity

A Loganayagam, Mónica Hernández, Adele Corrigan et al. · British Journal of Cancer · 2013 · 175 citations · Full text

Medicine, Oncology, Pharmacology +17

PharmGKB summary

Caroline F. Thorn, Sharon Marsh, Michelle Whirl‐Carrillo et al. · Pharmacogenetics and Genomics · 2010 · 128 citations · Full text

Medicine, Pharmacology, Clinical Pharmacology +1

Chemotherapy-induced neurotoxicity: the value of neuroprotective strategies.

Antoinetta J. M. Beijers, Joost L.M. Jongen, Gerard Vreugdenhil · PubMed · 2012 · 123 citations

Medicine, Neuroscience, Oncology +14

A Polymorphism in the <i>Cytidine Deaminase</i> Promoter Predicts Severe Capecitabine-Induced Hand-Foot Syndrome

Daniela Caronia, Miguel Martín, Javier Sastre et al. · Clinical Cancer Research · 2011 · 85 citations · Full text

Medicine, Genetics, Pharmacology +13

Which Gene is a Dominant Predictor of Response During FOLFOX Chemotherapy for the Treatment of Metastatic Colorectal Cancer, the MTHFR or XRCC1 Gene?

Kwang Wook Suh, Joo Hyung Kim, Do Yoon Kim et al. · Annals of Surgical Oncology · 2006 · 70 citations

Medicine, Genetics, Oncology +12